C Frank Bennett sold $2.3M of IONS
EVP, Chief Scientific Officer at IONIS PHARMACEUTICALS INC. 38,909 shares at an average of $59.14, traded Sep 2, 2025, filed Sep 4, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.3M at market
- +10Share of holdings soldSold 42% of holdings
- +15Cluster13 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000213, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2025 | SOpen-market sale Common Stock10b5-1 | -5,000 | $49.14 | $246k | 88,679 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +46,800 | $53.77 | $2.5M | 135,479 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -33,909 | $60.62 | $2.1M | 101,570 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | -12,891 | $61.50 | $793k | 88,679 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -46,800 | $0.00 | $0 | 0 | Sep 4, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IONIS PHARMACEUTICALS INC | Joseph H Wender director | $2.3M 28,000 shares | -44% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $1.4M 16,777 shares | -49% | |
| 39Weak | IONIS PHARMACEUTICALS INC | Joseph Klein III director | $960k 12,000 shares | -300% | |
| 60Notable | IONIS PHARMACEUTICALS INC | Joan E Herman director | $3.2M 44,000 shares | -76% | |
| 35Weak | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $609k 8,000 shares | -14% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Richard S Geary EVP, Chief Development Officer | $2.6M 34,639 shares | -57% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Richard S Geary EVP, Chief Development Officer | $6.8M 90,929 shares | -80% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Joseph Loscalzo director | $1.2M 16,000 shares | -31% | |
| 45Moderate | IONIS PHARMACEUTICALS INC | Joseph H Wender director | $2.1M 28,000 shares | -30% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $1.7M 23,900 shares | -35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.